对于心室节律失常的金尼丁:一个全面的审查
Redwane Rakza1, Pierre Groussin1, Karim Benali2
1Univ Rennes, CHU Rennes, INSERM, LTSI - UMR 1099, F-35000 Rennes, France.
Trends in cardiovascular medicine
|July 30, 2024
概括
作为一种基本的抗心律失常药物,金尼丁正在恢复对治疗复杂心室心律失常的重要性. 本次审查探讨了其当前的指示,支持证据,以及安全和可访问使用的未来方向.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
- 临床医学 临床医学
背景情况:
- 奎尼丁是一种开创性的Ia类抗失律药物,在20世纪被广泛使用.
- 20世纪90年代使用量下降的原因是安全问题和新的替代品.
- 最近的研究强调了素在特定的,通常是耐火的心室心律失常症中的有效性.
研究的目的:
- 综合审查当前欧洲和美国关于素使用的建议.
- 探索基于证据的素的适用情况,特别是在具有挑战性的心律失常症中.
- 讨论未来的研究需求,安全缓解和素的可获得性.
主要方法:
- 欧洲和美国临床指南的文献综述.
- 对支持在各种心脏病中使用素的研究进行分析.
- 关于Ia类抗节律药物的药理动力学和性作用的讨论.
主要成果:
- 奎尼丁仍然对布鲁加达综合征,异常心室动,早期再极化综合征,短QT综合征和电风暴有价值.
- 证据支持其在其他抗失常药物失败的地方发挥作用.
- 该综述综合了关于素治疗应用的当前知识.
结论:
- 奎尼丁是针对特定的,严重的心室节律失常的关键治疗选择.
- 需要进一步的研究,以优化患者的选择,并最大限度地降低阳性风险.
- 确保公平获取素对于患者护理至关重要.
相关概念视频
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
1.3K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
1.3K
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
952
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
952
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
812
Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
812
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
727
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
727
Mechanism of Cardiac Arrhythmias
909
Arrhythmias are irregular heart rhythms occurring when the heart's electrical impulses become abnormal. These disturbances can lead to various symptoms, depending on their severity and the underlying cause. Some common factors contributing to arrhythmias include hypoxia, ischemia, electrolyte imbalances, excessive catecholamine exposure, drug toxicity, and muscle overstretching. Arrhythmias can be classified into two main types based on the rate and site of origin of abnormal heart rhythms.
909
Antianginal Drugs: Calcium Channel Blockers and Ranolazine
481
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
481


